Conference Paper: Switching to lamivudine in entecavir-treated patients with undetectable HBV DNA - final results at 96 weeks

File Download

re01.htm

Links for fulltext
(May Require Subscription)

Publisher Website: 10.1002/hep.23990
Find via

Supplementary

Citations:
- Scopus:
- Web of Science:
- PubMed Central:
Item Statistics (The Hub)
Appears in Collections:
- Medicine: Conference papers

Title	Switching to lamivudine in entecavir-treated patients with undetectable HBV DNA - final results at 96 weeks
Authors	Fung, J Lai, CL Wong, D Seto, WK Yuen, MF
Keywords	Medical sciences Gastroenterology
Issue Date	2010
Publisher	John Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation	The 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010), Vienna, Austria, 14-18 April 2010. In Hepatology, 2010, v. 52 suppl. S1, p. 549A, abstract no. 462 [How to Cite?] DOI: http://dx.doi.org/10.1002/hep.23990
Abstract	BACKGROUND: The aim of this study was to determine the efficacy of entecavir followed by lamivudine in patients with undetectable viral load and normal ALT after initial entecavir treatment. METHODS: This is a 2-year prospective trial of 50 patients treated on entecavir 0.5 mg daily for over 6 months, and had …
ISSN	0270-9139 2011 Impact Factor: 11.665 2011 SCImago Journal Rankings: 1.278
DOI	http://dx.doi.org/10.1002/hep.23990

DC Field	Value
dc.contributor.author	Fung, J
dc.contributor.author	Lai, CL
dc.contributor.author	Wong, D
dc.contributor.author	Seto, WK
dc.contributor.author	Yuen, MF
dc.date.accessioned	2011-08-26T14:33:10Z
dc.date.available	2011-08-26T14:33:10Z
dc.date.issued	2010
dc.description.abstract	BACKGROUND: The aim of this study was to determine the efficacy of entecavir followed by lamivudine in patients with undetectable viral load and normal ALT after initial entecavir treatment. METHODS: This is a 2-year prospective trial of 50 patients treated on entecavir 0.5 mg daily for over 6 months, and had …
dc.description.nature	link_to_OA_fulltext
dc.description.other	The 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010), Vienna, Austria, 14-18 April 2010. In Hepatology, 2010, v. 52 suppl. S1, p. 549A, abstract no. 462
dc.identifier.citation	The 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010), Vienna, Austria, 14-18 April 2010. In Hepatology, 2010, v. 52 suppl. S1, p. 549A, abstract no. 462 [How to Cite?] DOI: http://dx.doi.org/10.1002/hep.23990
dc.identifier.doi	http://dx.doi.org/10.1002/hep.23990
dc.identifier.epage	549A
dc.identifier.hkuros	190375
dc.identifier.issn	0270-9139 2011 Impact Factor: 11.665 2011 SCImago Journal Rankings: 1.278
dc.identifier.issue	suppl. S1
dc.identifier.openurl
dc.identifier.spage	549A
dc.identifier.uri	http://hdl.handle.net/10722/137775
dc.identifier.volume	52
dc.language	eng
dc.publisher	John Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
dc.relation.ispartof	Hepatology
dc.rights	Hepatology. Copyright © John Wiley & Sons, Inc.
dc.subject	Medical sciences
dc.subject	Gastroenterology
dc.title	Switching to lamivudine in entecavir-treated patients with undetectable HBV DNA - final results at 96 weeks
dc.type	Conference_Paper

<?xml encoding="utf-8" version="1.0"?><item><contributor.author>Fung, J</contributor.author><contributor.author>Lai, CL</contributor.author><contributor.author>Wong, D</contributor.author><contributor.author>Seto, WK</contributor.author><contributor.author>Yuen, MF</contributor.author><date.accessioned>2011-08-26T14:33:10Z</date.accessioned><date.available>2011-08-26T14:33:10Z</date.available><date.issued>2010</date.issued><identifier.citation>The 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010), Vienna, Austria, 14-18 April 2010. In Hepatology, 2010, v. 52 suppl. S1, p. 549A, abstract no. 462</identifier.citation><identifier.issn>0270-9139</identifier.issn><identifier.uri>http://hdl.handle.net/10722/137775</identifier.uri><description.abstract>BACKGROUND: The aim of this study was to determine the efficacy of entecavir followed by lamivudine in patients with undetectable viral load and normal ALT after initial entecavir treatment. METHODS: This is a 2-year prospective trial of 50 patients treated on entecavir 0.5 mg daily for over 6 months, and had &#8230;</description.abstract><language>eng</language><publisher>John Wiley &amp; Sons, Inc. The Journal&apos;s web site is located at http://www.hepatology.org/</publisher><relation.ispartof>Hepatology</relation.ispartof><rights>Hepatology. Copyright &#169; John Wiley &amp; Sons, Inc.</rights><subject>Medical sciences</subject><subject>Gastroenterology</subject><title>Switching to lamivudine in entecavir-treated patients with undetectable HBV DNA -  final results at 96 weeks</title><type>Conference_Paper</type><identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0270-9139&amp;volume=52&amp;issue=Suppl. S1&amp;spage=549A, abstract no. 462&amp;epage=&amp;date=2010&amp;atitle=Switching+to+lamivudine+in+entecavir-treated+patients+with+undetectable+HBV+DNA+-++final+results+at+96+weeks</identifier.openurl><description.nature>link_to_OA_fulltext</description.nature><identifier.doi>10.1002/hep.23990</identifier.doi><identifier.hkuros>190375</identifier.hkuros><identifier.volume>52</identifier.volume><identifier.issue>suppl. S1</identifier.issue><identifier.spage>549A</identifier.spage><identifier.epage>549A</identifier.epage><description.other>The 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010), Vienna, Austria, 14-18 April 2010. In Hepatology, 2010, v. 52 suppl. S1, p. 549A, abstract no. 462</description.other><bitstream.url>http://hub.hku.hk/bitstream/10722/137775/1/re01.htm</bitstream.url></item>